SWOG clinical trial number
S1007

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone-responsive and Her2-Negative Breast Cancer according to Recurrence Score (RS).

100% Accrual
Accrual
100%
Closed
Phase
100% Accrual
Accrual
100%
Abbreviated Title
ADJUVANT: Phase III Randomized Endocrine Therapy +/- Chemo according to RS
Status Notes
4/9/21: S1007 Revision #16 protocol and supporting documents are being distributed to sites to begin the participating site implementation process. S1007 Revision #16 is CIRB approved, however SWOG is awaiting final contract execution with the processing laboratories in order to activate the Circulating Biomarker Assessment for Late Relapse Translational Medicine (CBALR TM) Substudy (Registration Step 3) to enrollment. A forthcoming memorandum will be distributed (anticipated May 2021) to activate the S1007 CBALR TM Substudy (Registration Step 3) and the provision of sample collection kits (as indicated in protocol Section 15.3b).

Step 1 Registration was closed to accrual effective October 1, 2015 and Step 2 Registration was closed to accrual effective October 15, 2015.
Activated
01/15/2011
Participants
NCORP, Members, Medical Oncologists, CTSU, Affiliates

Research committees

Breast Cancer

Treatment

Cyclophosphamide 5-Fluorouracil Paclitaxel Docetaxel Doxorubicin Tamoxifen Letrozole Epirubicin Anastrozole

Other Clinical Trials